In a study by Waanders et al., genomic variants in relapse-driver genes, such as CREBBP, IKZF1, and NT5C2, were rarely lost if present at diagnosis or in early therapy phase of ALL. Here, NT5C2 is linked to acute lymphoblastic leukemia.